Apogee Therapeutics Inc Financials
This page shows Apogee Therapeutics Inc (APGE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Apogee is operating as an equity-funded development company, with R&D-led cash burn accelerating faster than any self-funding capacity.
From FY2023 to FY2025, operating cash outflow widened from-$74.8M to-$227.5M while free cash flow stayed only modestly worse, showing cash use is being driven mainly by research operations rather than heavy capital spending. Just as important, the gap between operating loss and cash burn stays fairly tight across those years, so the reported losses are largely cash losses rather than accounting effects that might reverse on their own.
In FY2025, R&D spending of
The balance sheet remains equity financed: FY2025 liabilities were just
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Apogee Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Apogee Therapeutics Inc carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 26.57, Apogee Therapeutics Inc holds $26.57 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Apogee Therapeutics Inc generates a -28.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -25.4% the prior year.
Apogee Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Apogee Therapeutics Inc generates $0.89 in operating cash flow (-$227.4M OCF vs -$255.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Apogee Therapeutics Inc's EBITDA was -$284.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 31.1% from the prior year.
Apogee Therapeutics Inc reported -$255.8M in net income in fiscal year 2025. This represents a decrease of 40.5% from the prior year.
Apogee Therapeutics Inc earned $-4.22 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 27.9% from the prior year.
Cash & Balance Sheet
Apogee Therapeutics Inc generated -$232.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 35.0% from the prior year.
Apogee Therapeutics Inc held $131.5M in cash against $0 in long-term debt as of fiscal year 2025.
Apogee Therapeutics Inc had 68M shares outstanding in fiscal year 2025. This represents an increase of 17.8% from the prior year.
Margins & Returns
Apogee Therapeutics Inc's ROE was -28.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.9 percentage points from the prior year.
Capital Allocation
Apogee Therapeutics Inc invested $214.7M in research and development in fiscal year 2025. This represents an increase of 27.9% from the prior year.
Apogee Therapeutics Inc invested $5.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 346.8% from the prior year.
APGE Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $60.8M | N/A | $54.2M-2.7% | $55.7M+20.1% | $46.4M | N/A | $45.7M+37.7% | $33.2M |
| SG&A Expenses | $22.0M | N/A | $17.1M-2.1% | $17.5M+4.5% | $16.7M | N/A | $13.0M+18.8% | $10.9M |
| Operating Income | -$82.8M | N/A | -$71.3M+2.6% | -$73.2M-16.0% | -$63.1M | N/A | -$58.7M-33.0% | -$44.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $79K | N/A | $61K-15.3% | $72K-13.3% | $83K | N/A | $0 | $0 |
| Net Income | -$74.1M | N/A | -$65.0M+1.6% | -$66.1M-19.4% | -$55.3M | N/A | -$49.0M-45.0% | -$33.8M |
| EPS (Diluted) | $-1.06 | N/A | $-1.11+1.8% | $-1.13-18.9% | $-0.95 | N/A | $-0.86-43.3% | $-0.60 |
APGE Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B+38.0% | $937.1M+49.7% | $626.2M-4.8% | $657.8M-7.9% | $714.2M-5.3% | $754.0M-2.9% | $776.3M-3.0% | $800.7M |
| Current Assets | $1.1B+44.8% | $741.4M+37.3% | $540.1M+4.6% | $516.1M-1.0% | $521.5M-1.5% | $529.7M-0.9% | $534.5M-21.6% | $681.9M |
| Cash & Equivalents | $451.8M+243.4% | $131.5M+21.9% | $107.9M-13.1% | $124.2M+16.2% | $106.9M-24.6% | $141.8M+19.4% | $118.8M-61.3% | $307.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $37.9M+13.9% | $33.3M-16.5% | $39.8M+3.8% | $38.4M-6.0% | $40.8M+9.8% | $37.2M-11.3% | $41.9M+55.0% | $27.0M |
| Current Liabilities | $33.0M+18.1% | $27.9M-18.0% | $34.0M+7.9% | $31.6M-4.3% | $33.0M+15.4% | $28.6M-12.4% | $32.6M+32.5% | $24.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.3B+38.9% | $903.9M+54.2% | $586.3M-5.3% | $619.4M-8.0% | $673.4M-6.1% | $716.8M-2.4% | $734.4M-5.1% | $773.6M |
| Retained Earnings | -$635.9M-13.2% | -$561.8M-14.1% | -$492.4M-15.2% | -$427.4M-18.3% | -$361.3M-18.1% | -$305.9M-28.2% | -$238.7M-25.8% | -$189.7M |
APGE Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$55.6M+11.4% | -$62.7M-15.5% | -$54.3M+12.5% | -$62.0M-28.0% | -$48.5M+28.4% | -$67.7M-59.2% | -$42.5M-45.1% | -$29.3M |
| Capital Expenditures | $4.3M+6862.9% | $62K | $0-100.0% | $768K-82.2% | $4.3M+431800.0% | -$1K-100.1% | $751K+1372.5% | $51K |
| Free Cash Flow | -$59.9M+4.6% | -$62.8M-15.7% | -$54.3M+13.6% | -$62.8M-18.9% | -$52.8M+22.0% | -$67.7M-56.5% | -$43.3M-47.4% | -$29.4M |
| Investing Cash Flow | -$35.3M+87.8% | -$288.6M-1708.4% | $17.9M-77.0% | $78.1M+501.8% | $13.0M-72.0% | $46.4M+131.7% | -$146.4M+1.6% | -$148.7M |
| Financing Cash Flow | $411.2M+9.7% | $374.9M+1799.6% | $19.7M+1572.7% | $1.2M+89.7% | $622K-98.6% | $44.4M+11481.2% | $383K+355.3% | -$150K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
APGE Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -5.9% | N/A | -11.1%-0.4pp | -10.7%-2.5pp | -8.2% | N/A | -6.7%-2.3pp | -4.4% |
| Return on Assets | -5.7% | N/A | -10.4%-0.3pp | -10.1%-2.3pp | -7.8% | N/A | -6.3%-2.1pp | -4.2% |
| Current Ratio | 32.59+6.0 | 26.57+10.7 | 15.86-0.5 | 16.36+0.5 | 15.82-2.7 | 18.55+2.2 | 16.39-11.3 | 27.70 |
| Debt-to-Equity | 0.030.0 | 0.04-0.0 | 0.070.0 | 0.060.0 | 0.060.0 | 0.050.0 | 0.06+0.0 | 0.03 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Apogee Therapeutics Inc profitable?
No, Apogee Therapeutics Inc (APGE) reported a net income of -$255.8M in fiscal year 2025.
What is Apogee Therapeutics Inc's EBITDA?
Apogee Therapeutics Inc (APGE) had EBITDA of -$284.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Apogee Therapeutics Inc's return on equity (ROE)?
Apogee Therapeutics Inc (APGE) has a return on equity of -28.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Apogee Therapeutics Inc's free cash flow?
Apogee Therapeutics Inc (APGE) generated -$232.6M in free cash flow during fiscal year 2025. This represents a -35.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Apogee Therapeutics Inc's operating cash flow?
Apogee Therapeutics Inc (APGE) generated -$227.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Apogee Therapeutics Inc's total assets?
Apogee Therapeutics Inc (APGE) had $937.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Apogee Therapeutics Inc's capital expenditures?
Apogee Therapeutics Inc (APGE) invested $5.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Apogee Therapeutics Inc spend on research and development?
Apogee Therapeutics Inc (APGE) invested $214.7M in research and development during fiscal year 2025.
What is Apogee Therapeutics Inc's current ratio?
Apogee Therapeutics Inc (APGE) had a current ratio of 26.57 as of fiscal year 2025, which is generally considered healthy.
What is Apogee Therapeutics Inc's debt-to-equity ratio?
Apogee Therapeutics Inc (APGE) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Apogee Therapeutics Inc's return on assets (ROA)?
Apogee Therapeutics Inc (APGE) had a return on assets of -27.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Apogee Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Apogee Therapeutics Inc (APGE) had $131.5M in cash against an annual operating cash burn of $227.4M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Apogee Therapeutics Inc's Piotroski F-Score?
Apogee Therapeutics Inc (APGE) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Apogee Therapeutics Inc's earnings high quality?
Apogee Therapeutics Inc (APGE) has an earnings quality ratio of 0.89x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Apogee Therapeutics Inc?
Apogee Therapeutics Inc (APGE) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.